The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).
 
Patrick Schoffski
Honoraria - Daiichi Sankyo; Eisai; Lilly; Medpace; Novartis; Swedish Orphan Biovitrum
Consulting or Advisory Role - 6th Element Capital; Adaptimmune; Amcure; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Cristal Therapeutics; Daiichi Sankyo; Eisai; Epizyme; Ipsen; Lilly; Loxo; Medpace; Nektar; Novartis; Philogen; Pique; Plexxikon; Sanofi
Speakers' Bureau - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Swedish Orphan Biovitrum
Research Funding - Bayer; Blueprint Medicines; Cobiores nv; Exelixis; GlaxoSmithKline; Novartis; Plexxikon
Travel, Accommodations, Expenses - 6th Element Capital; Adaptimmune; Amcure; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Cristal Therapeutics; Daiichi Sankyo; Eisai; Epizyme; Ipsen; Lilly; Loxo; Medpace; Nektar; Novartis; PharmaMar; Philogen; Pique; Plexxikon; Sanofi; Swedish Orphan Biovitrum
 
Mark Agulnik
Consulting or Advisory Role - Eisai; Janssen; Lilly; Novartis
Speakers' Bureau - Eisai; Janssen; Novartis
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Karyopharm Therapeutics; Lilly; PharmaMar; Plexxikon
Research Funding - Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Lara Emily Davis
Consulting or Advisory Role - Eisai
Research Funding - Epizyme; Karyopharm Therapeutics; Lilly
 
Victor Manuel Villalobos
Consulting or Advisory Role - Janssen; Lilly; Novartis
Travel, Accommodations, Expenses - Lilly
 
Antoine Italiano
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbvie
Research Funding - Blueprint Medicines; Deciphera; Novartis; Pfizer
 
Gregory Michael Cote
Consulting or Advisory Role - Advance Medical; InfiniteMD
Research Funding - Agios (Inst); Amgen (Inst); Boston Biomedical (Inst); Epizyme (Inst); Macrogenics (Inst); Otsuka (Inst); PharmaMar (Inst)
 
Stephen Blakemore
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Alicia Clawson
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Scott Daigle
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
Patents, Royalties, Other Intellectual Property - Patents Relating to Pinometostat methods of use including combination and indications
Travel, Accommodations, Expenses - Epizyme
 
Scott Ribich
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
Research Funding - Epizyme
Patents, Royalties, Other Intellectual Property - Epizyme
 
Maria Roche
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Jill Rodstrom
Employment - Epizyme
 
Peter T.C. Ho
Employment - Epizyme
Leadership - Epizyme
Stock and Other Ownership Interests - BeiGene; Epizyme; Johnson & Johnson
Consulting or Advisory Role - Lilly Asia Ventures
 
Mrinal M. Gounder
Honoraria - Amgen; Daiichi Sankyo; Karyopharm Therapeutics; TRACON Pharma
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Karyopharm Therapeutics